CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,150,134 | +136.8% | 744,816 | +43.5% | 0.01% | +133.3% |
| Q2 2023 | $9,353,979 | +29.6% | 519,109 | +15.5% | 0.00% | +50.0% |
| Q1 2023 | $7,220,275 | +77445.6% | 449,605 | -11.6% | 0.00% | -33.3% |
| Q4 2022 | $9,311 | -99.9% | 508,848 | -5.1% | 0.00% | -25.0% |
| Q3 2022 | $10,528,000 | +1.9% | 536,070 | -3.2% | 0.00% | 0.0% |
| Q2 2022 | $10,329,000 | -3.8% | 553,871 | +13.2% | 0.00% | +33.3% |
| Q1 2022 | $10,736,000 | +9.4% | 489,357 | +41.7% | 0.00% | 0.0% |
| Q4 2021 | $9,814,000 | +49.7% | 345,444 | +11.0% | 0.00% | +50.0% |
| Q3 2021 | $6,554,000 | +87.6% | 311,344 | +68.0% | 0.00% | +100.0% |
| Q2 2021 | $3,493,000 | +247.9% | 185,293 | +181.9% | 0.00% | – |
| Q1 2021 | $1,004,000 | +197.9% | 65,720 | +175.0% | 0.00% | – |
| Q4 2020 | $337,000 | – | 23,895 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |